Page 317 - Glucose Monitoring Devices

324 CHAPTER 15 Automated closed-loop insulin delivery

[26] Steil GM, Clark B, Kanderian S, Rebrin K. Modeling insulin action for development of
a closed-loop artificial pancreas. Diabetes Technology and Therapeutics 2005;7(1):
94e108.
[27] Bequette BW. Challenges and recent progress in the development of a closed-loop arti-
ficial pancreas. Annual Reviews in Control 2012;36(2):255e66.
[28] Cameron FM, et al. Closed-loop control without meal announcement in type 1 diabetes.
Diabetes Technology and Therapeutics 2017;19(9):527e32.
[29] Gondhalekar R, Dassau E, Doyle FJ. Periodic zone-MPC with asymmetric costs for
outpatient-ready safety of an artificial pancreas to treat type 1 diabetes. Automatica
2016;71:237e46.
[30] Toffanin C, Zisser H, Doyle FJ, Dassau E. Dynamic insulin on board: incorporation of
circadian insulin sensitivity variation. Journal of Diabetes Science and Technology
2013;7(4):928e40.
[31] Lee H, Bequette BW. A closed-loop artificial pancreas based on model predictive con-
trol: human-friendly identification and automatic meal disturbance rejection. Biomed-
ical Signal Processing and Control 2009;4(4):347e54.
[32] Hovorka R, et al. Nonlinear model predictive control of glucose concentration in sub-
jects with type 1 diabetes. Physiological Measurement 2004;25(4):905.
[33] Cameron F, Niemeyer G, Bequette BW. Extended multiple model prediction with appli-
cation to blood glucose regulation. Journal of Process Control 2012;22(8):1422e32.
[34] Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop
control of type 1 diabetes what systems are in development? Journal of Diabetes Sci-
ence and Technology 2016;10(3):714e23.
[35] Del Favero S, et al. Multicenter outpatient dinner/overnight reduction of hypoglycemia
and increased time of glucose in target with a wearable artificial pancreas using modular
model predictive control in adults with type 1 diabetes. Diabetes, Obesity and Meta-
bolism 2015;17(5):468e76.
[36] Del Favero S, et al. Randomized summer camp crossover trial in 5-to 9-year-old chil-
dren: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care 2016:
dc152815.
[37] Messori M, et al. Individually adaptive artificial pancreas in subjects with type 1 dia-
betes: a one-month proof-of-concept trial in free-living conditions. Diabetes Technol-
ogy and Therapeutics 2017;19(10):560e71.
[38] Breton MD, et al. Closed loop control during intense prolonged outdoor exercise in ad-
olescents with type 1 diabetes: the artificial pancreas Ski study. Diabetes Care 2017;
40(12):1644e50.
[39] Turksoy K, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive identification and
control for artificial pancreas systems. IEEE Transactions on Biomedical Engineering
2014;61(3):883e91.
[40] Turksoy K, Bayrak ES, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive closed-
loop control of an artificial pancreas without meal and activity announcement. Diabetes
Technology and Therapeutics 2013;15(5):386e400.
[41] Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis, and relationship to
hypoglycemia in diabetes. Diabetes Care 2016;39(4):502e10.
[42] Jacobs PG, et al. Automated control of an adaptive bihormonal, dual-sensor artificial
pancreas and evaluation during inpatient studies. IEEE Transactions on Biomedical En-
gineering 2014;61(10):2569e81.